These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 19609217)

  • 1. Metastatic carcinoid tumor: changing patterns of care over two decades.
    Townsend A; Price T; Yeend S; Pittman K; Patterson K; Luke C
    J Clin Gastroenterol; 2010 Mar; 44(3):195-9. PubMed ID: 19609217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma.
    Shojamanesh H; Gibril F; Louie A; Ojeaburu JV; Bashir S; Abou-Saif A; Jensen RT
    Cancer; 2002 Jan; 94(2):331-43. PubMed ID: 11900219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of type I gastric neuroendocrine tumors with somatostatin analogs.
    Khuroo MS; Khuroo MS; Khuroo NS
    J Gastroenterol Hepatol; 2010 Mar; 25(3):548-54. PubMed ID: 20074162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metastatic neuroendocrine hepatic tumors: resection improves survival.
    Musunuru S; Chen H; Rajpal S; Stephani N; McDermott JC; Holen K; Rikkers LF; Weber SM
    Arch Surg; 2006 Oct; 141(10):1000-4; discussion 1005. PubMed ID: 17043278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival.
    Gupta S; Johnson MM; Murthy R; Ahrar K; Wallace MJ; Madoff DC; McRae SE; Hicks ME; Rao S; Vauthey JN; Ajani JA; Yao JC
    Cancer; 2005 Oct; 104(8):1590-602. PubMed ID: 16134179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group.
    di Bartolomeo M; Bajetta E; Buzzoni R; Mariani L; Carnaghi C; Somma L; Zilembo N; di Leo A
    Cancer; 1996 Jan; 77(2):402-8. PubMed ID: 8625251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Management of digestive system carcinoid tumors and carcinoid syndrome].
    Mondragón Sánchez RJ; Castillero Pinilla C; Saldívar Moreno C; Oñate Ocaña LF; Ruiz Molina JM; Aiello Crocifoglio V
    Rev Gastroenterol Mex; 1998; 63(4):204-10. PubMed ID: 10319670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors.
    Eriksson BK; Larsson EG; Skogseid BM; Löfberg AM; Lörelius LE; Oberg KE
    Cancer; 1998 Dec; 83(11):2293-301. PubMed ID: 9840528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.
    Wolin EM; Jarzab B; Eriksson B; Walter T; Toumpanakis C; Morse MA; Tomassetti P; Weber MM; Fogelman DR; Ramage J; Poon D; Gadbaw B; Li J; Pasieka JL; Mahamat A; Swahn F; Newell-Price J; Mansoor W; Öberg K
    Drug Des Devel Ther; 2015; 9():5075-86. PubMed ID: 26366058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A clinical overview of carcinoid tumors: perspectives for improvement in treatment using peptide analogs (review).
    Comaru-Schally AM; Schally AV
    Int J Oncol; 2005 Feb; 26(2):301-9. PubMed ID: 15645113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver.
    Chung MH; Pisegna J; Spirt M; Giuliano AE; Ye W; Ramming KP; Bilchik AJ
    Surgery; 2001 Dec; 130(6):954-62. PubMed ID: 11742323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR.
    Toumpanakis C; Garland J; Marelli L; Srirajaskanthan R; Soh J; Davies P; Buscombe J; Caplin ME
    Aliment Pharmacol Ther; 2009 Oct; 30(7):733-40. PubMed ID: 19573169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single dose of octreotide stabilize metastatic gastro-entero-pancreatic endocrine tumours.
    Angeletti S; Corleto VD; Schillaci O; Moretti A; Panzuto F; Annibale B; Delle Fave G
    Ital J Gastroenterol Hepatol; 1999; 31(1):23-7. PubMed ID: 10091100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors.
    Frank M; Klose KJ; Wied M; Ishaque N; Schade-Brittinger C; Arnold R
    Am J Gastroenterol; 1999 May; 94(5):1381-7. PubMed ID: 10235222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of hepatic metastasis of gastrointestinal carcinoid tumors.
    Landry CS; Scoggins CR; McMasters KM; Martin RC
    J Surg Oncol; 2008 Mar; 97(3):253-8. PubMed ID: 18264984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
    Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
    Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours.
    Turner GB; Johnston BT; McCance DR; McGinty A; Watson RG; Patterson CC; Ardill JE
    Gut; 2006 Nov; 55(11):1586-91. PubMed ID: 16556667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatostatin receptor expression in vivo and response to somatostatin analog therapy with or without other antineoplastic treatments in advanced medullary thyroid carcinoma.
    Vainas I; Koussis Ch; Pazaitou-Panayiotou K; Drimonitis A; Chrisoulidou A; Iakovou I; Boudina M; Kaprara A; Maladaki A
    J Exp Clin Cancer Res; 2004 Dec; 23(4):549-59. PubMed ID: 15743023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy of somatostatin analogs in the treatment of neuroendocrine tumours and paraneoplastic syndromes].
    Sperlongano P; De Falco M; Pisaniello D; Parmeggiani D; Parmeggiani U
    Minerva Endocrinol; 2001 Dec; 26(4):293-5. PubMed ID: 11782719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors.
    Osborne DA; Zervos EE; Strosberg J; Boe BA; Malafa M; Rosemurgy AS; Yeatman TJ; Carey L; Duhaine L; Kvols LK
    Ann Surg Oncol; 2006 Apr; 13(4):572-81. PubMed ID: 16511671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.